Investigates the effectiveness of 18F-FDG PET/CT in detecting tumors in individuals with neurofibromatosis type 1, suggesting improved management options.
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder that predisposes affected individuals to benign and malignant tumors throughout their lifetime. Early detection of those lesions is critical for effective management. PET/CT with 18F-fluorodeoxyglucose (18F-FDG) has emerged as a potentially efficient modality for detecting malignant tumors in patients with NF1. The aim of this study was to investigate this hypothesis by assessing the presence of incidental findings of malignant and potentially malignant tumors using 18F-FDG PET/CT in an adult NF1 cohort.
No takes yet. Share an insight, caveat, or question.
Tanase et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: